MSB 2.26% 90.5¢ mesoblast limited

Ann: Third Quarter Results Presentation, page-13

  1. 430 Posts.
    lightbulb Created with Sketch. 93
    Hoping Lonza s learnt their lessons from past FDA inspections.

    https://www.fiercepharma.com/manufacturing/fda-blasts-lonza-facility-form-483-derailed-bristol-myers-plan-liso-cel-nod-by-2020

    FDA blasts Lonza facility in Form 483 that derailed Bristol Myers' plan of liso-cel nod by 2020

    'Lonza didn’t exactly have a clean slate when it comes cell therapy manufacturing. Back in 2017, the Swiss CDMO’s facility in Walkersville, Maryland, was hit with an FDA warning letter over issues including validation and aseptic process simulations.'
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
90.5¢
Change
0.020(2.26%)
Mkt cap ! $1.033B
Open High Low Value Volume
88.5¢ 95.0¢ 88.0¢ $5.610M 6.115M

Buyers (Bids)

No. Vol. Price($)
12 317774 90.0¢
 

Sellers (Offers)

Price($) Vol. No.
91.5¢ 23500 2
View Market Depth
Last trade - 16.10pm 06/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.